Febuxostat, a New Treatment Option for Hyperuricemia and Gout

What Is Hyperuricemia?

Hyperuricemia is a state in which serum uric acid levels exceed 7.0 mg/dL. When left untreated, uric acid can no longer be completely dissolved into the blood and so it crystallizes, forming deposits around the body. The condition often leads to gouty attacks and complications such as renal impairment and urinary stone formation.

More Choice for Patients

Teijin developed febuxostat, a treatment for hyperuricemia and gout, which suppresses the formation of uric acid in the body by blocking enzymes. Hyperuricemia and gout were previously not widely recognized in society, but as a new treatment option, febuxostat has been acknowledged by various awards, including the Japanese Prime Minister’s Award, which is helping to promote awareness of the disease. While only permitted for gout treatment overseas at the moment, the aim is to include hyperuricemia treatment in the future.

Delivering to 117 Markets around the World

As of March 2017, febuxostat has been launched in over 60 countries and territories including the United States, Canada, Europe and Korea. Expansion will continue with a goal of reaching 117 countries and territories including China, Southeast Asia, Oceania, Central and South America, the Middle East and North Africa. Teijin is always challenging their aim to be a global leader in the treatment of hyperuricemia and gout.